ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

Application of Premixed Insulin NovoMix®30 and NovoRapid® as Multiple Daily Injections or as Basal Bolus Format in Selected Diabetic Patients: Practical Evidence from Prospective Case Series

Journal: International Journal of Diabetology & Vascular Disease Research (IJDVR) (Vol.05, No. e)

Publication Date:

Authors : ;

Page : 1-2

Keywords : hypoglycemia; human insulin; glargine (Lantus®); detemir (Levemir®) and degludec (Tresiba®); bolus or mealtime insulins analogs;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

Managing type-1 or type-2 diabetes by insulin is one of the best techniques, especially for type-2 diabetics after oral hypoglycemic agents (OHAs) failure. Multiple daily injections (MDI) or basal bolus methodology is an ideal regimen for type-1 diabetics [1, 2]. However, it is a difficult option for type-2 diabetic patients, especially older age groups. Most of type-2 diabetics usually prefer two injections per day, in the morning and evening. Analog premixed biphasic insulins include NovoMix® 30, Humalog Mix® 25 and Humalog Mix® 50. These insulin analogs are also recommended because of their safety and efficacy as compared to older or traditional insulins (Human Regular Insulin such as Humulin® R and Actrapid®, neutral protamine Hagedorn or NPH and their mixtures of premixed human insulin 30/70), which are associated with more frequent hypoglycemia. Safety and efficacy of insulin analogs have also been demonstrated during Ramadan fasting

Last modified: 2017-05-30 15:10:02